Pancreatic Cancer Research

ResearcherMayo ClinicNo recent work listed

Haojie Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2751-6413; OpenAlex author ID A5024723808. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2013: 2 papers · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 3 papers

Papers 8

  1. Establishing and validating an ADCP-related prognostic signature in pancreatic ductal adenocarcinoma. Last author DOI 10.18632/aging.204221↗
  2. Single-cell sequencing reveals heterogeneity between pancreatic adenosquamous carcinoma and pancreatic ductal adenocarcinoma with prognostic value. Co-author DOI 10.3389/fimmu.2022.972298↗
  3. Methods of a New Chronic Pancreatitis and Spontaneous Pancreatic Cancer Mouse Model Using Retrograde Pancreatic Duct Injection of Dibutyltin Dichloride. Last author DOI 10.3389/fonc.2022.947133↗
  4. Identification and Validation of Three PDAC Subtypes and Individualized GSVA Immune Pathway-Related Prognostic Risk Score Formula in Pancreatic Ductal Adenocar… Co-author DOI 10.1155/2021/4986227↗
  5. HPP1 gene promoter methylation in pancreatic cancer: correlation with carcinogenesis and clinical implication. Co-author PMID 31949740↗
  6. Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction. Last author DOI 10.1158/0008-5472.can-16-3143↗
  7. ABCB2 (TAP1) as the downstream target of SHH signaling enhances pancreatic ductal adenocarcinoma drug resistance. Co-author DOI 10.1016/j.canlet.2013.01.002↗
  8. A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Co-author DOI 10.1053/j.gastro.2013.08.018↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Deyu Zhang · 4 shared papers, 2021–2022 · strength 0.58
  2. Hua Yin · 3 shared papers, 2021–2022 · strength 0.44
  3. Lisi Peng · 3 shared papers, 2018–2022 · strength 0.35
  4. Zhendong Jin · 2 shared papers, 2021–2022 · strength 0.27
  5. Huanhai Xu · 1 shared paper, 2022 · strength 0.14
  6. Lu Zhuang · 1 shared paper, 2018 · strength 0.08
  7. Zhaoshen Li · 1 shared paper, 2018 · strength 0.08
  8. Yang Zhang · 1 shared paper, 2018 · strength 0.08
  9. Kun Lin · 1 shared paper, 2018 · strength 0.08
  10. Kaixuan Wang · 1 shared paper, 2018 · strength 0.08
  11. Lizhi Zhang · 1 shared paper, 2017 · strength 0.07
  12. Tao Ma · 1 shared paper, 2017 · strength 0.07
  13. Heshui Wu · 1 shared paper, 2017 · strength 0.07
  14. Xin Jin · 1 shared paper, 2017 · strength 0.07
  15. Amy Tang · 1 shared paper, 2017 · strength 0.07
  16. Daniel D. Billadeau · 1 shared paper, 2017 · strength 0.07
  17. Youli Zhang · 1 shared paper, 2013 · strength 0.04
  18. Xiangyu Kong · 1 shared paper, 2013 · strength 0.04
  19. Min Xu · 1 shared paper, 2013 · strength 0.04
  20. Lei Li · 1 shared paper, 2013 · strength 0.04
  21. Bincy Philip · 1 shared paper, 2013 · strength 0.03
  22. Jarosław Daniluk · 1 shared paper, 2013 · strength 0.03
  23. Huamin Wang · 1 shared paper, 2013 · strength 0.03
  24. Deyali Chatterjee · 1 shared paper, 2013 · strength 0.03
  25. Yan Liu · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.